Global Complement Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

According to APO Research, The global Complement Inhibitors market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Complement Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Complement Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Complement Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Complement Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Complement Inhibitors include Alexion Pharmaceuticals, Amgen, Apellis Pharmaceuticals, Astellas Pharma, CSL Behring, Pharming Healthcare, Regeneron Pharmaceuticals, Samsung Bioepis and UCB, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Complement Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Complement Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for Complement Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Complement Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Complement Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Complement Inhibitors sales, projected growth trends, production technology, application and end-user industry.

Complement Inhibitors Segment by Company

Alexion Pharmaceuticals
Amgen
Apellis Pharmaceuticals
Astellas Pharma
CSL Behring
Pharming Healthcare
Regeneron Pharmaceuticals
Samsung Bioepis
UCB
Roche
Novartis
Sanofi
Takeda
Complement Inhibitors Segment by Type

Complement Factor D Inhibitor
Complement Factor B Inhibitor
Complement C5 Inhibitors
Complement C3 Inhibitors
C1 Esterase Inhibitors
Complement Inhibitors Segment by Application

Geographic Atrophy (GA)
Atypical Hemolytic Uremic Syndrome (aHUS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Others
Complement Inhibitors Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Complement Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Complement Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Complement Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Complement Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Complement Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Complement Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Complement Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Complement Inhibitors Market Size, 2020 VS 2024 VS 2031
1.3 Global Complement Inhibitors Market Size Estimates and Forecasts (2020-2031)
1.4 Global Complement Inhibitors Sales Estimates and Forecasts (2020-2031)
1.5 Global Complement Inhibitors Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Complement Inhibitors Market Dynamics
2.1 Complement Inhibitors Industry Trends
2.2 Complement Inhibitors Industry Drivers
2.3 Complement Inhibitors Industry Opportunities and Challenges
2.4 Complement Inhibitors Industry Restraints
3 Complement Inhibitors Market by Manufacturers
3.1 Global Complement Inhibitors Revenue by Manufacturers (2020-2025)
3.2 Global Complement Inhibitors Sales by Manufacturers (2020-2025)
3.3 Global Complement Inhibitors Average Sales Price by Manufacturers (2020-2025)
3.4 Global Complement Inhibitors Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Complement Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Complement Inhibitors Manufacturers, Product Type & Application
3.7 Global Complement Inhibitors Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Complement Inhibitors Market CR5 and HHI
3.8.2 Global Top 5 and 10 Complement Inhibitors Players Market Share by Revenue in 2024
3.8.3 2024 Complement Inhibitors Tier 1, Tier 2, and Tier 3
4 Complement Inhibitors Market by Type
4.1 Complement Inhibitors Type Introduction
4.1.1 Complement Factor D Inhibitor
4.1.2 Complement Factor B Inhibitor
4.1.3 Complement C5 Inhibitors
4.1.4 Complement C3 Inhibitors
4.1.5 C1 Esterase Inhibitors
4.2 Global Complement Inhibitors Sales by Type
4.2.1 Global Complement Inhibitors Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Complement Inhibitors Sales by Type (2020-2031)
4.2.3 Global Complement Inhibitors Sales Market Share by Type (2020-2031)
4.3 Global Complement Inhibitors Revenue by Type
4.3.1 Global Complement Inhibitors Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Complement Inhibitors Revenue by Type (2020-2031)
4.3.3 Global Complement Inhibitors Revenue Market Share by Type (2020-2031)
5 Complement Inhibitors Market by Application
5.1 Complement Inhibitors Application Introduction
5.1.1 Geographic Atrophy (GA)
5.1.2 Atypical Hemolytic Uremic Syndrome (aHUS)
5.1.3 Paroxysmal Nocturnal Hemoglobinuria (PNH)
5.1.4 Others
5.2 Global Complement Inhibitors Sales by Application
5.2.1 Global Complement Inhibitors Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Complement Inhibitors Sales by Application (2020-2031)
5.2.3 Global Complement Inhibitors Sales Market Share by Application (2020-2031)
5.3 Global Complement Inhibitors Revenue by Application
5.3.1 Global Complement Inhibitors Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Complement Inhibitors Revenue by Application (2020-2031)
5.3.3 Global Complement Inhibitors Revenue Market Share by Application (2020-2031)
6 Global Complement Inhibitors Sales by Region
6.1 Global Complement Inhibitors Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Complement Inhibitors Sales by Region (2020-2031)
6.2.1 Global Complement Inhibitors Sales by Region (2020-2025)
6.2.2 Global Complement Inhibitors Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Complement Inhibitors Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Complement Inhibitors Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Complement Inhibitors Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Complement Inhibitors Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Complement Inhibitors Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Complement Inhibitors Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Complement Inhibitors Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Complement Inhibitors Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Complement Inhibitors Revenue by Region
7.1 Global Complement Inhibitors Revenue by Region
7.1.1 Global Complement Inhibitors Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Complement Inhibitors Revenue by Region (2020-2025)
7.1.3 Global Complement Inhibitors Revenue by Region (2026-2031)
7.1.4 Global Complement Inhibitors Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Complement Inhibitors Revenue (2020-2031)
7.2.2 North America Complement Inhibitors Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Complement Inhibitors Revenue (2020-2031)
7.3.2 Europe Complement Inhibitors Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Complement Inhibitors Revenue (2020-2031)
7.4.2 Asia-Pacific Complement Inhibitors Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Complement Inhibitors Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Complement Inhibitors Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Alexion Pharmaceuticals
8.1.1 Alexion Pharmaceuticals Comapny Information
8.1.2 Alexion Pharmaceuticals Business Overview
8.1.3 Alexion Pharmaceuticals Complement Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Alexion Pharmaceuticals Complement Inhibitors Product Portfolio
8.1.5 Alexion Pharmaceuticals Recent Developments
8.2 Amgen
8.2.1 Amgen Comapny Information
8.2.2 Amgen Business Overview
8.2.3 Amgen Complement Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Amgen Complement Inhibitors Product Portfolio
8.2.5 Amgen Recent Developments
8.3 Apellis Pharmaceuticals
8.3.1 Apellis Pharmaceuticals Comapny Information
8.3.2 Apellis Pharmaceuticals Business Overview
8.3.3 Apellis Pharmaceuticals Complement Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Apellis Pharmaceuticals Complement Inhibitors Product Portfolio
8.3.5 Apellis Pharmaceuticals Recent Developments
8.4 Astellas Pharma
8.4.1 Astellas Pharma Comapny Information
8.4.2 Astellas Pharma Business Overview
8.4.3 Astellas Pharma Complement Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Astellas Pharma Complement Inhibitors Product Portfolio
8.4.5 Astellas Pharma Recent Developments
8.5 CSL Behring
8.5.1 CSL Behring Comapny Information
8.5.2 CSL Behring Business Overview
8.5.3 CSL Behring Complement Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 CSL Behring Complement Inhibitors Product Portfolio
8.5.5 CSL Behring Recent Developments
8.6 Pharming Healthcare
8.6.1 Pharming Healthcare Comapny Information
8.6.2 Pharming Healthcare Business Overview
8.6.3 Pharming Healthcare Complement Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Pharming Healthcare Complement Inhibitors Product Portfolio
8.6.5 Pharming Healthcare Recent Developments
8.7 Regeneron Pharmaceuticals
8.7.1 Regeneron Pharmaceuticals Comapny Information
8.7.2 Regeneron Pharmaceuticals Business Overview
8.7.3 Regeneron Pharmaceuticals Complement Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Regeneron Pharmaceuticals Complement Inhibitors Product Portfolio
8.7.5 Regeneron Pharmaceuticals Recent Developments
8.8 Samsung Bioepis
8.8.1 Samsung Bioepis Comapny Information
8.8.2 Samsung Bioepis Business Overview
8.8.3 Samsung Bioepis Complement Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Samsung Bioepis Complement Inhibitors Product Portfolio
8.8.5 Samsung Bioepis Recent Developments
8.9 UCB
8.9.1 UCB Comapny Information
8.9.2 UCB Business Overview
8.9.3 UCB Complement Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 UCB Complement Inhibitors Product Portfolio
8.9.5 UCB Recent Developments
8.10 Roche
8.10.1 Roche Comapny Information
8.10.2 Roche Business Overview
8.10.3 Roche Complement Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Roche Complement Inhibitors Product Portfolio
8.10.5 Roche Recent Developments
8.11 Novartis
8.11.1 Novartis Comapny Information
8.11.2 Novartis Business Overview
8.11.3 Novartis Complement Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Novartis Complement Inhibitors Product Portfolio
8.11.5 Novartis Recent Developments
8.12 Sanofi
8.12.1 Sanofi Comapny Information
8.12.2 Sanofi Business Overview
8.12.3 Sanofi Complement Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Sanofi Complement Inhibitors Product Portfolio
8.12.5 Sanofi Recent Developments
8.13 Takeda
8.13.1 Takeda Comapny Information
8.13.2 Takeda Business Overview
8.13.3 Takeda Complement Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Takeda Complement Inhibitors Product Portfolio
8.13.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Complement Inhibitors Value Chain Analysis
9.1.1 Complement Inhibitors Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Complement Inhibitors Production Mode & Process
9.2 Complement Inhibitors Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Complement Inhibitors Distributors
9.2.3 Complement Inhibitors Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings